Vindesine in plasma cell tumors

L. Salvagno, A. Paccagnella, V. Chiarion Sileni, P. De Besi, M. Frizzarin, D. Casara, M. V. Fiorentino

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-one patients with plasma cell tumors received vindesine (VDS) at the dose of 3 mg/m2 i.v. on day 1 plus prednisone at the dose of 100 mg p.o. from day 1 to 5, recycling every 8 days 3 times and then every 10-12 days. In 3 patients with gastric or duodenal ulcer prednisone was not administered. All but one patient were heavily pretreated and resistant to M-2 regimen. Overall there were 4 objective responses (19%): 2 among 15 patients (13%) with multiple myeloma and 2 among 6 patients (33%) with extramedullary plasmacytoma (EMP). The responses lasted for 2, 12, 15 and 48+ months. One previously untreated EMP patients received VDS without prednisone and obtained a complete long-lasting remission. The association of VDS with high-dose prednisone seems to have some activity in plasma cell tumors; probably in multiple myeloma the objective responses are due to the high dose of cortisone rather than to VDS. On the contrary, in EMP patients, VDS may be an active agent, even if administered without cortisone.

Original languageEnglish
Pages (from-to)533-536
Number of pages4
JournalTumori
Volume71
Issue number6
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research

Fingerprint

Dive into the research topics of 'Vindesine in plasma cell tumors'. Together they form a unique fingerprint.

Cite this